> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Maternal RSV Vaccine Cuts Severe Infant Illness 81.8% in First 90 Days in Phase 3 Interim Analysis
- URL: https://www.theamericanquorum.com/taq-historical-2022-11-05-healthcare/
- Published: 2022-11-06T03:59:00.000Z
- Updated: 2022-11-06T03:59:00.000Z
- Description: Pfizer reported 81.8% efficacy against severe medically attended RSV illness in infants through 90 days after birth in a Phase 3 maternal-vaccination interim analysis.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 18:54

Pfizer this week reported that its experimental maternal respiratory syncytial virus vaccine reduced severe medically attended RSV lower respiratory tract illness in infants by 81.8% during the first 90 days after birth in a planned interim analysis of a large Phase 3 trial. The company's [November 1 announcement](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global?ref=theamericanquorum.com) also reported 69.4% efficacy against severe illness through the first six months of life, results that could move the field closer to a long-sought way of protecting newborns during the period when RSV can be most dangerous.

The investigational vaccine, called RSVpreF, is administered during pregnancy with the goal of generating maternal antibodies that cross the placenta and protect the infant after birth. Pfizer said the trial met the prespecified statistical success criterion for one of its two primary efficacy endpoints. The second primary endpoint—medically attended RSV lower respiratory tract illness of any severity—showed clinically meaningful efficacy but did not meet the trial's prespecified statistical criterion for success. That distinction is important: the interim result is strongest for preventing severe disease rather than demonstrating the same degree of certainty for all medically attended RSV illness.

## Protection is aimed at the first vulnerable months of life

RSV is a common respiratory virus, but its burden is concentrated among the youngest children and older adults. A Centers for Disease Control and Prevention [infant RSV briefing](https://stacks.cdc.gov/view/cdc/122462?ref=theamericanquorum.com) estimates that tens of thousands of U.S. children younger than five are hospitalized with RSV each year, with the highest risk of severe disease among very young infants, premature infants and children with certain underlying conditions.

Maternal immunization is designed around a biological window that pediatric vaccination cannot easily cover. Newborns are too young for many routine vaccine schedules, yet they can receive antibodies developed by the pregnant parent before delivery. That approach has already been used for other diseases, including influenza and pertussis. Pfizer's program attempts to apply the same principle to RSV by targeting the virus's prefusion F protein, a structure involved in viral entry into cells.

The Phase 3 study, known as MATISSE, is registered as [NCT04424316](https://clinicaltrials.gov/study/NCT04424316?ref=theamericanquorum.com). It is designed to evaluate both safety and efficacy in pregnant participants and their infants across multiple countries. Pfizer said the interim analysis was conducted by an independent external data-monitoring committee and that no safety concerns were identified for vaccinated pregnant participants or their newborns at the time of the announcement.

## The severe-disease endpoint cleared the statistical bar

For severe medically attended lower respiratory tract illness, Pfizer reported vaccine efficacy of 81.8%, with a confidence interval of 40.6% to 96.3%, during the first 90 days of life. Through six months, efficacy was 69.4%, with a confidence interval of 44.3% to 84.1%. The wider range around the early estimate reflects statistical uncertainty even though the point estimate is high.

For the broader medically attended lower respiratory tract illness endpoint, the company reported 57.1% efficacy during the first 90 days and 51.3% through six months. Those estimates did not satisfy the protocol's prespecified statistical success criterion. A responsible reading of the data therefore separates the positive severe-disease finding from the more uncertain broader endpoint rather than treating the entire trial as uniformly successful.

The Phase 3 program builds on earlier maternal-immunization work. A randomized Phase 2b study registered as [NCT04032093](https://clinicaltrials.gov/study/NCT04032093?ref=theamericanquorum.com) evaluated the same prefusion F vaccine concept in pregnant women. Results published in the [New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2106062?ref=theamericanquorum.com) provided safety, immunogenicity and efficacy information that informed the larger pivotal program.

## A vaccine platform being tested at both ends of the age spectrum

Pfizer is developing RSVpreF not only for maternal immunization but also for older adults, another population with substantial risk from RSV. In March, the company announced that the Food and Drug Administration had granted [Breakthrough Therapy designation](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-granted-fda-breakthrough-therapy-designation-0?ref=theamericanquorum.com) to its older-adult RSV vaccine candidate based on earlier study data. The company separately received [Breakthrough Therapy designation](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-granted-fda-breakthrough-therapy-designation?ref=theamericanquorum.com) for the maternal program.

The dual strategy reflects the epidemiology of RSV. Infants can develop bronchiolitis and pneumonia requiring hospitalization, while older adults—particularly those with cardiopulmonary disease or frailty—can also experience serious lower respiratory tract disease. A single vaccine antigen platform, if ultimately proven safe and effective in separate populations, could address two different high-risk periods using different vaccination strategies.

National Institutes of Health-supported research has long emphasized the importance of stabilizing the RSV F protein in its prefusion configuration. That structural approach helped researchers identify potent neutralizing-antibody targets and has become central to several modern RSV vaccine programs. The broader scientific effort is described in NIH-supported work on the [structure-based design](https://www.nih.gov/news-events/nih-research-matters/structure-based-design-vaccine-respiratory-syncytial-virus?ref=theamericanquorum.com) of RSV vaccine antigens.

## The next step is regulatory review, not a finished verdict

Pfizer said it plans to submit the maternal RSV vaccine for regulatory review by the end of 2022\. That filing will require regulators to examine the full safety database, manufacturing information, endpoint definitions, statistical analysis and the balance of benefits and risks. Top-line trial results, even from a large randomized study, are not the same as approval.

The safety question is especially consequential for a vaccine given during pregnancy. Regulators will need to evaluate outcomes in both pregnant participants and infants and determine whether the timing of vaccination produces a favorable benefit-risk profile. The MATISSE trial's design and the accumulated Phase 2 experience provide a substantial evidence base, but the detailed dataset has not yet been reviewed publicly by the FDA.

If the severe-disease result is confirmed through regulatory review, the practical significance could be considerable. RSV has remained a persistent pediatric problem precisely because the youngest infants enter their first respiratory-virus season before they can mount mature immune responses of their own. A maternal vaccine would seek to shift protection earlier—before exposure—by borrowing immunity from pregnancy. This week's Phase 3 result does not settle every question, but it provides the strongest evidence yet from Pfizer's program that the approach can materially reduce the most serious RSV illness during an infant's first months of life.